查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965793

光遗传学致动器和感测器市场－全球产业规模、份额、趋势、机会、预测：按产品、疾病类型、地区和竞争格局划分，2021-2031年

Optogenetics Actuators and Sensors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球光遗传学致动器和感测器市场预计将从 2025 年的 12.1 亿美元成长到 2031 年的 17.1 亿美元，复合年增长率达到 5.93%。

该领域包括生物仪器，使科学家能够利用光精确控制和观察神经功能。致动器利用光敏蛋白来影响神经细胞的放电，而感测器则利用萤光标记物来即时视觉化细胞讯号。推动这一领域发展的主要动力是神经系统疾病发病率上升带来的日益沉重的负担，这使得人们更需要先进的脑迴路分析技术来开发新的治疗方法。例如，根据阿兹海默症协会估计，到2025年，约有720万65岁及以上的美国人将患有老年痴呆症失智症，凸显了利用这些研究技术加速药物研发的紧迫性。

市场概览
预测期 2027-2031
市场规模：2025年 12.1亿美元
市场规模：2031年 17.1亿美元
复合年增长率：2026-2031年 5.93%
成长最快的细分市场 致动器
最大的市场 北美洲

另一方面，这些系统固有的复杂技术规范和高昂实施成本构成了巨大的市场障碍。实施这些先进工具需要昂贵的光学设备和分子生物学专业知识，这实际上限制了它们的使用，使其仅限于资金雄厚的学术机构和专业研究设施。除了这些高进入门槛之外，目前颅内光照射的侵入性要求也限制了其在临床环境中的广泛应用，使得大部分市场成长局限于临床前研究领域。

市场驱动因素

生技公司与学术机构之间的策略合作，以及大量的私人投资，是推动光遗传学解决方案发展的主要动力。这些合作对于将理论分子生物学转化为实际临床应用至关重要，尤其是在退化性视网膜疾病的视力恢復领域。合作研究可以显着降低病毒载体设计和临床试验的高成本。例如，2024年1月，Kiora Pharmaceuticals宣布与Thea Open Innovation达成一项价值高达3.01亿美元的策略协议，旨在推进用于治疗遗传性视网膜疾病的小分子光开关的研发。这标誌着该行业从学术研究向商业化治疗的重大转变。

此外，全球神经系统疾病发病率的上升推动了对能够调节特定脑迴路的精确致动器的需求日益增长。由于传统药物通常缺乏必要的空间分辨率，针对与癫痫等疾病相关的特定神经通路的光遗传学干预变得愈发迫切。根据世界卫生组织（WHO）2024年3月的报告，目前全球有超过34亿人患有神经系统疾病，因此开发新的治疗方法迫在眉睫。这种需求正在推动大量的资本投资；例如，Beacon Therapeutics在2024年完成了1.7亿美元的B轮资金筹措，以加速眼科基因疗法的研发。这反映了对尖端医疗技术的强劲资金支持。

市场挑战

光遗传学的广泛应用主要受其复杂的技术要求和高昂的实施成本限制。利用这些先进工具需要对专用光学基础设施进行大量投资，包括精密雷射、光纤介面和高速记录设备。此外，有效操作这些仪器需要光学工程和分子生物学的专业知识，而这类技能稀少且取得成本极高。高昂的基础设施成本和对专业人员的需求使得市场主要局限于顶尖学术机构，难以渗透到小规模实验室和临床环境。

对外部研究津贴的严重依赖加剧了这一障碍，使得研究人员极易受到经费削减的影响。高昂的设备购买成本意味着，科学界的财政紧缩会立即限制采购活动。例如，2024年，神经科学学会指出，联邦政府对「脑计画」（倡议）的拨款——该计画是神经技术设备购置的关键资金来源——被削减至4.02亿美元。这项大幅削减严重限制了可用于购买先进实验设备的资金。此类预算限制迫使实验室推迟或放弃购置必要的传感器和致动器，直接阻碍了市场成长。

市场趋势

视网膜色素变性光遗传治疗方法的临床进展标誌着从理论神经科学到实际恢復人类视力的重大转变。这一趋势的标誌是，不依赖突变的视蛋白成功进入后期临床试验阶段，证明光敏蛋白可以重新运作严重视力障碍患者的视网膜迴路。现代疗法正摆脱对复杂外部硬体的依赖，转而专注于在环境光下工作的高灵敏度致动器。 2024年10月，Nanoscope Therapeutics公司报告称，一项MCO-010疗法的随机试验显示，患者的最佳矫正视力得到了具有统计学意义的显着改善（约0.3 LogMAR），证实了该疗法在恢復功能性视力方面的有效性。

同时，利用微型LED阵列实现的光传输系统小型化正在革新神经刺激技术，使其能够实现高解析度的植入式介面。这项技术突破克服了传统光纤连接的局限性，将超高密度光源嵌入可适应生物组织的柔性薄膜基板上。这些混合设备将基因疗法与先进工程技术相结合，能够以极高的空间精度靶向特定的神经层。为了佐证这项进展，Science Corporation于2024年4月宣布将收购Pixium的视网膜植入技术，以增强其Science Eye设备。 Science Eye设备独特地将光遗传学基因疗法与可植入的柔性微型LED显示器结合，从而直接刺激视网膜神经节细胞。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球光遗传学致动器和感测器市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按产品（致动器、感测器）
    • 疾病类型（视网膜疾病、帕金森氏症、焦虑/忧郁症、自闭症、思觉失调症、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美光遗传学致动器和感测器市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲光遗传学致动器和感测器的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区光遗传学致动器和感测器市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲光遗传学致动器和感测器的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美光遗传学致动器和感测器的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球光遗传学致动器和感测器市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Inscopix
  • Thorlabs
  • Hamamatsu
  • NeuroNexus
  • OptoGenTech
  • Boston Micromachines
  • Nanoscribe
  • Cyrus Biosystems
  • Blueberry Therapeutics
  • Neurolight

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 25406

The Global Optogenetics Actuators & Sensors Market is projected to expand from USD 1.21 Billion in 2025 to USD 1.71 Billion by 2031, achieving a compound annual growth rate of 5.93%. This sector encompasses biological instruments that allow scientists to precisely regulate and observe neural functions via light; actuators utilize photosensitive proteins to influence neuronal firing, while sensors employ fluorescent markers to image cellular signals in real time. A key factor propelling this growth is the increasing burden of neurological conditions, which fuels the need for sophisticated brain circuitry analysis to identify novel therapeutic avenues. For instance, the Alzheimer's Association estimates that in 2025, approximately 7.2 million Americans aged 65 or older will have Alzheimer's dementia, highlighting the urgent need for these investigative technologies to expedite drug discovery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.21 Billion
Market Size 2031USD 1.71 Billion
CAGR 2026-20315.93%
Fastest Growing SegmentActuators
Largest MarketNorth America

Conversely, the market faces significant hurdles due to the complex technical specifications and substantial implementation costs inherent to these systems. Deploying these advanced tools necessitates costly optical equipment and specialized knowledge in molecular biology, effectively limiting their use to adequately funded academic centers and specialized research facilities. This high barrier to entry, combined with the invasive requirement for intracranial light delivery, currently restricts broad clinical adoption and confines the majority of market growth to preclinical research environments.

Market Driver

Strategic partnerships between biotechnology companies and academic institutions, supported by significant private investment, serve as a major engine for the progress of optogenetic solutions. These alliances are crucial for converting theoretical molecular biology into practical clinical applications, especially regarding vision restoration for degenerative retinal conditions. Collaborative efforts allow entities to mitigate the substantial expenses linked to viral vector engineering and clinical testing. To illustrate, Kiora Pharmaceuticals announced in January 2024 that it entered a strategic agreement with Thea Open Innovation, valued at up to $301 million, to advance a small molecule photoswitch for treating inherited retinal diseases, marking a decisive industry move from academic research to commercial therapeutics.

Additionally, the escalating global incidence of neurological disorders drives the demand for precise actuators capable of modulating specific brain circuits. Because traditional pharmaceuticals often lack necessary spatial resolution, there is a pressing need for optogenetic interventions that target distinct neural pathways associated with diseases like epilepsy. According to a March 2024 World Health Organization release, neurological conditions now affect over 3.4 billion individuals globally, establishing a critical requirement for novel treatment modalities. This demand has triggered substantial capital investment; for example, Beacon Therapeutics secured $170 million in Series B financing in 2024 to speed up ophthalmic gene therapy development, reflecting the strong financial backing for these cutting-edge medical technologies.

Market Challenge

The widespread adoption of optogenetics is severely hindered by the intricate technical demands and prohibitive costs associated with implementing these systems. Utilizing such sophisticated tools requires substantial investment in specialized optical infrastructure, including precision lasers, fiber-optic interfaces, and high-speed recording equipment. Moreover, operating this machinery effectively calls for advanced expertise in both optical engineering and molecular biology, a skill set that is both rare and expensive to secure. This combination of high infrastructure costs and the need for specialized personnel largely confines the market to elite academic institutions, preventing deeper penetration into smaller labs and clinical environments.

This obstacle is further aggravated by the market's strong dependence on external research grants, rendering it highly vulnerable to reductions in funding availability. The substantial cost of ownership implies that fiscal tightening within the scientific community immediately restricts procurement activities. For instance, the Society for Neuroscience noted in 2024 that federal funding for the BRAIN Initiative-a vital source for acquiring neurotechnology-was slashed to $402 million, a sharp reduction that significantly limited the funds available for purchasing advanced experimental tools. Such budgetary constraints directly hamper market growth by compelling laboratories to postpone or abandon the acquisition of necessary sensors and actuators.

Market Trends

The clinical advancement of optogenetic therapies for Retinitis Pigmentosa marks a pivotal shift from theoretical neuroscience to the tangible restoration of human vision. This trend is defined by the successful progression of mutation-agnostic opsins into late-stage clinical trials, proving that light-sensitive proteins can reactivate retinal circuitry in individuals with profound vision loss. Modern approaches have moved beyond complex external hardware to favor high-sensitivity actuators that function under ambient light. In October 2024, Nanoscope Therapeutics reported that patients in their randomized trial for the MCO-010 therapy achieved a statistically significant improvement in best-corrected visual acuity of roughly 0.3 LogMAR, confirming the treatment's efficacy in restoring functional vision.

In parallel, the miniaturization of light delivery systems via micro-LED arrays is transforming neural stimulation by facilitating high-resolution, implantable interfaces. This technological leap resolves the constraints of traditional fiber-optic tethering by embedding ultra-dense light sources on flexible thin-film substrates that adapt to biological tissue. These hybrid devices merge gene therapy with advanced engineering to target specific neuronal layers with exceptional spatial precision. As evidence of this progress, Science Corporation announced in April 2024 the acquisition of Pixium's retinal implant technology to enhance its Science Eye device, which uniquely combines optogenetic gene therapy with an implanted flexible micro-LED display to directly stimulate retinal ganglion cells.

Key Market Players

  • Inscopix
  • Thorlabs
  • Hamamatsu
  • NeuroNexus
  • OptoGenTech
  • Boston Micromachines
  • Nanoscribe
  • Cyrus Biosystems
  • Blueberry Therapeutics
  • Neurolight

Report Scope

In this report, the Global Optogenetics Actuators & Sensors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optogenetics Actuators & Sensors Market, By Product

  • Actuators
  • Sensors

Optogenetics Actuators & Sensors Market, By Disease Type

  • Retinal Disorders
  • Parkinson's Disease
  • Anxiety & Depression
  • Autism
  • Schizophrenia
  • Others

Optogenetics Actuators & Sensors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optogenetics Actuators & Sensors Market.

Available Customizations:

Global Optogenetics Actuators & Sensors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optogenetics Actuators & Sensors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Actuators, Sensors)
    • 5.2.2. By Disease Type (Retinal Disorders, Parkinson's Disease, Anxiety & Depression, Autism, Schizophrenia, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Optogenetics Actuators & Sensors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Optogenetics Actuators & Sensors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Disease Type
    • 6.3.2. Canada Optogenetics Actuators & Sensors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Disease Type
    • 6.3.3. Mexico Optogenetics Actuators & Sensors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Disease Type

7. Europe Optogenetics Actuators & Sensors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Optogenetics Actuators & Sensors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Disease Type
    • 7.3.2. France Optogenetics Actuators & Sensors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Disease Type
    • 7.3.3. United Kingdom Optogenetics Actuators & Sensors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Disease Type
    • 7.3.4. Italy Optogenetics Actuators & Sensors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Disease Type
    • 7.3.5. Spain Optogenetics Actuators & Sensors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Disease Type

8. Asia Pacific Optogenetics Actuators & Sensors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Optogenetics Actuators & Sensors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Disease Type
    • 8.3.2. India Optogenetics Actuators & Sensors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Disease Type
    • 8.3.3. Japan Optogenetics Actuators & Sensors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Disease Type
    • 8.3.4. South Korea Optogenetics Actuators & Sensors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Disease Type
    • 8.3.5. Australia Optogenetics Actuators & Sensors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Disease Type

9. Middle East & Africa Optogenetics Actuators & Sensors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Optogenetics Actuators & Sensors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Disease Type
    • 9.3.2. UAE Optogenetics Actuators & Sensors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Disease Type
    • 9.3.3. South Africa Optogenetics Actuators & Sensors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Disease Type

10. South America Optogenetics Actuators & Sensors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Disease Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Optogenetics Actuators & Sensors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Disease Type
    • 10.3.2. Colombia Optogenetics Actuators & Sensors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Disease Type
    • 10.3.3. Argentina Optogenetics Actuators & Sensors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Disease Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Optogenetics Actuators & Sensors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Inscopix
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thorlabs
  • 15.3. Hamamatsu
  • 15.4. NeuroNexus
  • 15.5. OptoGenTech
  • 15.6. Boston Micromachines
  • 15.7. Nanoscribe
  • 15.8. Cyrus Biosystems
  • 15.9. Blueberry Therapeutics
  • 15.10. Neurolight

16. Strategic Recommendations

17. About Us & Disclaimer